Secondary analysis of OPT-BIRISK: in 4072 bleeding- and ischaemic-risk ACS patients with diabetes, 9 months of clopidogrel monotherapy vs clopidogrel plus aspirin cut BARC 2, 3 or 5 bleeding (2.1% vs 3.2%; HR 0.66) without more MACCE; consistent without diabetes.
Secondary analysisn = 7,758
Zhang et al. Clopidogrel Versus Dual-Antiplatelet Therapy for Long-Term Maintenance After Coronary Stenting in Ischemic and Bleeding Birisk Patients With Acute Coronary Syndromes and Diabetes: A Prespecified Subgroup Analysis of the OPT-BIRISK Trial